top of page

Cytokinetics’ CEO Robert Blum discusses today’s SEQUOIA-HCM P3 result

Robert Blum describes Aficamten’s topline safety, efficacy, and how the company views its competitive profile.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page